IP Library Granted Patent US 10,927,393
Granted Patent B2
US 10,927,393 · App. 13/913,153 · Granted Feb 23, 2021

Nucleic acid amplifications

Inventors: Honghua Zhang (San Diego, CA); Jarrod Provins (Dana Point, CA); Richard Roth (Carlsbad, CA)
Assignee: Ionian Technologies, LLC
C12P19/34C12Q1/6846
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,927,393
App. No.
13/913,153
Granted
Feb 23, 2021
Kind
B2
Abstract

A method includes combining a polynucleotide and an amplification reagent mixture to form a reaction mixture, wherein the reaction mixture comprises reversibly bound divalent ions in solution, and adjusting the pH of the reaction mixture to release the reversibly bound divalent ions, thereby initiating amplification of the polynucleotide.

Claims (41)

1. A method comprising:

(a) combining a polynucleotide and an amplification reagent mixture at a first temperature between 10° C. and 30° C. to form a reaction mixture, wherein the amplification reagent mixture comprises a polymerase, magnesium ions, a temperature-sensitive buffer, and a multidentate pH-sensitive chelating agent, wherein the ratio of the multidentate pH-sensitive chelating agent concentration to the magnesium ion concentration is from about 0.5 to about 2;

(b) adjusting the temperature of the reaction mixture from

(i) said first temperature at which the pH of the temperature-sensitive buffer is operable for the pH-sensitive chelating agent to reversibly bind free magnesium ions in solution, such that amplification of the polynucleotide is inhibited, to

(ii) a second temperature between 40° C. and 70° C. at which the pH of the temperature-sensitive buffer is operable to release bound magnesium ions from the pH-sensitive chelating agent, such that amplification of the polynucleotide can proceed; and

(c) amplifying the polynucleotide at said second temperature without repeated cycling of the temperature of the reaction mixture between the first temperature and the second temperature.

2. The method of claim 1 , wherein the reaction mixture comprises a free magnesium ion concentration at the first temperature that is between about 0 and about 10 mM.

3. The method of claim 1 , wherein the reaction mixture comprises a free magnesium ion concentration at the first temperature that is between about 0 and about 5 mM.

4. The method of claim 1 , wherein the reaction mixture comprises a free magnesium ion concentration at the first temperature that is between about 0 and about 2 mM.

5. The method of claim 1 , wherein the reaction mixture comprises a free magnesium ion concentration at the first temperature that is between about 0 and about 1 mM.

6. The method of claim 1 , wherein the reaction mixture comprises a free magnesium ion concentration at the first temperature that is between about 0 and about 0.2 mM.

7. The method of claim 1 , wherein the reaction mixture comprises a free magnesium ion concentration at the first temperature that is between about 0 and about 0.1 mM.

8. The method of claim 1 , wherein the reaction mixture comprises a free magnesium ion concentration at the second temperature that is between about 5 mM and about 50 mM.

9. The method of claim 1 , wherein the reaction mixture comprises a free magnesium ion concentration at the second temperature that is between about 10 mM and about 50 mM.

10. The method of claim 1 , wherein the reaction mixture comprises a free magnesium ion concentration at the second temperature that is between about 10 mM and about 20 mM.

11. The method of claim 1 , wherein the reaction mixture comprises a free magnesium ion concentration at the second temperature that is between about 5 mM and about 20 mM.

12. The method of claim 1 , wherein the reaction mixture comprises a free magnesium ion concentration at the second temperature that is between about 5 mM and about 10 mM.

13. The method of claim 1 , wherein the multidentate pH-sensitive chelating agent is selected from the group consisting of ethyleneglycol-bis(2-aminoethylether) tetraacetic acid, EGTA derivatives, and EDTA derivatives.

14. The method of claim 1 , wherein the pKa of the temperature-sensitive buffer at the second temperature is at least 0.4 less than the pKa of the temperature-sensitive buffer at the first temperature.

15. The method of claim 1 , wherein the temperature-sensitive buffer comprises tris(hydroxymethyl)aminomethane.

16. The method of claim 1 , wherein the first temperature is between 10° C. and about 20° C. or between about 20° C. and 30° C.

17. The method of claim 1 , wherein the first temperature is between about 20° C. and 30° C.

18. The method of claim 1 , wherein the second temperature is between 40° C. and about 50° C., between about 50° C. and about 60° C., or between about 60° C. and 70° C.

19. The method of claim 1 , wherein the second temperature is between about 60° C. and 70° C.

20. The method of claim 1 , wherein the amplification reagent mixture comprises a nicking endonuclease.

21. The method of claim 1 , wherein the amplification reagent mixture comprises a DNA polymerase or an RNA polymerase.

22. The method of claim 1 , wherein the amplification reagent mixture comprises a reverse transcriptase.

23. The method of claim 1 , wherein the amplification reagent mixture comprises:

(1) a first oligonucleotide comprising a 5′ portion that comprises a nicking site and that is non-complementary to a target sequence of the polynucleotide and a 3′ portion that hybridizes to the target sequence of the polynucleotide; and

(2) a second oligonucleotide comprising a 5′ portion that comprises a nicking site and that is non-complementary to the target sequence of the polynucleotide and a 3′ portion that hybridizes to the target sequence of the polynucleotide.

24. The method of claim 1 , wherein amplification of the polynucleotide occurs under substantially isothermal conditions.

25. The method of claim 1 , wherein the polynucleotide is not denatured prior to combining with the amplification reagent mixture.

26. The method of claim 1 , further comprising:

(d) detecting amplified polynucleotides.

27. The method of claim 1 , wherein one or more components of the amplification reagent mixture is provided in a container suitable for use in a fluidic device, cartridge, or lateral flow device.

28. A method comprising:

(a) combining a polynucleotide and an amplification reagent mixture at a first temperature between 10° C. and 30° C. to form a reaction mixture, wherein the amplification reagent mixture comprises a polymerase, magnesium ions, a temperature sensitive buffer, and a multidentate pH-sensitive chelating agent selected from the group consisting of EDTA, EDTA derivatives, EGTA, and EGTA derivatives, wherein the ratio of the multidentate pH-sensitive chelating agent concentration to the magnesium ion concentration is from about 0.5 to about 2;

(b) adjusting the temperature of the reaction mixture from

(i) said first temperature at which the pH of the temperature-sensitive buffer is operable for the multidentate pH-sensitive chelating agent to reversibly bind free magnesium ions from solution, such that amplification of the polynucleotide is inhibited, to

(ii) a second temperature between 40° C. and 70° C. at which the pH of the temperature-sensitive buffer is operable to release bound magnesium ions from the multidentate pH-sensitive chelating agent to solution, such that amplification of the polynucleotide can proceed; and

(c) amplifying the polynucleotide at said second temperature.

Assignments (8)
CORRECTIVE ASSIGNMENT TO CORRECT THE ATTACHED DOCUMENT PREVIOUSLY RECORDED AT REEL: 052673 FRAME: 0682. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Jan 6, 2022
From: ALERE HEALTH IMPROVEMENT COMPANY
To: NEWCO RD, LLC
Reel/Frame 058565/0833 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2020
From: ALERE HEALTH IMPROVEMENT COMPANY
To: NEWCO RD, LLC
Reel/Frame 052673/0682 →
CHANGE OF NAME Recorded May 15, 2020
From: NEWCO RD, LLC
To: IONIAN TECHNOLOGIES, LLC
Reel/Frame 052679/0239 →
MERGER Recorded Mar 13, 2020
From: IONIAN TECHNOLOGIES INC.
To: ALERE HEALTH IMPROVEMENT COMPANY
Reel/Frame 052111/0050 →
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498 Recorded Oct 5, 2017
From: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT
To: ALERE CONNECT, LLC; ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.); ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.); INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA AMEDITECH INC.); IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES, INC.); QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.); STANDING STONE, LLC; ESCREEN, INC.
Reel/Frame 044213/0258 →
ASSIGNMENT OF IP SECURITY AGREEMENT, PREVIOUSLY RECORDED AT REEL 036994, FRAME 0192 Recorded Nov 16, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS RETIRING ADMINISTRATIVE AGENT
To: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR ADMINISTRATIVE AGENT
Reel/Frame 037115/0498 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 29, 2015
From: ALERE CONNECT, LLC; ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.); ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.); INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA AMEDITECH INC.); IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES, INC.); QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.); STANDING STONE, LLC; ESCREEN, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 036994/0192 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2013
From: ZHANG, HONGHUA; PROVINS, JARROD; ROTH, RICHARD
To: IONIAN TECHNOLOGIES, INC.
Reel/Frame 030576/0141 →
Continuity (3)
Provisional Application 61657227 · Jun 8, 2012
Provisional Application 61782199 · Mar 14, 2013
Related Publication 20130330777A1 · Dec 12, 2013